Endometrial cancer treatment by tumor suppressor microRNA
Project/Area Number |
25462608
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Keio University |
Principal Investigator |
BANNO KOUJI 慶應義塾大学, 医学部, 講師 (70265875)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 子宮体癌 / エピジェネティクス / miR-34b / メチル化 / 癌抑制型microRNA |
Outline of Final Research Achievements |
[Objective] microRNAs have key roles in the onset, development and drug resistance of cancer. We identified miR-34b as a tumor suppressor-type microRNA with expression that is epigenetically suppressed in endometrial cancer. In this study, the antitumor effect of combined miR-34b and antitumor drugs on endometrial cancer was examined. [Results] There was no change in cell viability after administration of miR-34b following application of cisplatin or adriamycin to HEC-108, HEC-1B and KLE cells. However, after treatment with paclitaxel, cell viability after administration of miR-34b decreased in all three cell lines. Tumor development occurred 14 days after transplantation of HEC-1B cells in nude mice. Drugs were administered on that day and thereafter. The tumor diameter significantly decreased in mice treated with paclitaxel + miR-34b compared with the results for other treatments (p<0.05).
|
Report
(3 results)
Research Products
(5 results)
-
[Journal Article] Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.2016
Author(s)
Irie H, Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.
-
Journal Title
Oncol Lett.
Volume: 11
Pages: 1287-1293
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Current status of molecular-targeted drugs for endometrial cancer (Review)2013
Author(s)
Nogami Y, Banno K, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D.
-
Journal Title
Mol Clin Oncol.
Volume: 1
Pages: 799-804
Related Report
Peer Reviewed
-
-
-